Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 42

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 42
---
           | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                       |     |           |   275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5)        |     |           | 1,380 |     | $        | 1,380,000 |

| (1) | Additional details regarding these stockholders and their equity                                                 
 holdings are included herein under the section “Security Ownership of Certain Beneficial Owners and Management.” |

| (2) | Daniel Corey served as the Chief Technology Officer and a member                                                                   
 of the board of directors from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific 
 Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024.     |

| (3) | Brian G. Atwood served as Chairman and Chief Executive                                                                                
 Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination 
 in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000.     |

| (4) | Chris Ehrlich has served as the Chairman and Chief Executive                                                             
 Officer since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer from October 2024 
 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, and (iii) the       
 Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024.                          |

| (5) | Phoenix Biotech Sponsor, LLC beneficially owned more than 5%     
 of our outstanding capital stock at the time of the transaction. |

Registered Direct Offering in February 2025 On February 7, 2025, we issued and sold 300,000 shares of our Common Stock and 2,251,020 Pre-Funded Warrants to purchase 2,251,020 shares of our Common Stock together with 2,551,020 February 2025 Common Warrants to purchase 2,551,020 shares of Common Stock. Each share of Common Stock or Pre-Funded Warrant is being sold together with a February